Airain Ltd’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Airain Ltd’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$758K	Sell	9,608 -4,284	-31%	-$350K	0.03%	461
2017 Q1	$1.15M	Buy	13,892 +4,809	+53%	+$358K	0.06%	320
2016 Q4	$721K	Buy	+9,083	New	+$660K	0.06%	298
2016 Q1	–	Sell	-2,423	Closed	-$215K	–	1114
2015 Q4	$215K	Sell	2,423 -2,715	-53%	-$214K	0.01%	707
2015 Q3	$380K	Sell	5,138 -3,724	-42%	-$310K	0.02%	545
2015 Q2	$717K	Buy	8,862 +966	+12%	+$62.9K	0.04%	433
2015 Q1	$331K	Buy	+7,896	New	+$224K	0.02%	608

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Airain Ltd's EGRX Position: Q2 2017 in Review

Airain Ltd reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 31% in Q2 2017, selling an estimated $350K and leaving 9,608 shares worth $758K. The position accounts for 0.03% of the portfolio, ranked #461.

Airain Ltd first reported a position in EGRX in Q1 2015 and has held it in 7 quarters since. The position peaked at $1.15M in Q1 2017. 175 funds tracked by Wall St. Rank hold EGRX as of Q2 2017.

Airain Ltd held 9,608 shares of Eagle Pharmaceuticals, Inc. worth $758K as of Q2 2017.
Airain Ltd sold 4,284 Eagle Pharmaceuticals, Inc. shares in Q2 2017, an estimated $350K.
Eagle Pharmaceuticals, Inc. made up 0.03% of Airain Ltd's portfolio in Q2 2017, its #461 holding.
Airain Ltd first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and has held it in 7 quarters since.
Airain Ltd's Eagle Pharmaceuticals, Inc. position peaked at $1.15M in Q1 2017.
175 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.